HIỆU QUẢ CỦA CAPECITABINE ĐƠN CHẤT TRONG ĐIỀU TRỊ DUY TRÌ UNG THƯ ĐẠI TRỰC TRÀNG DI CĂN TẠI BỆNH VIỆN K

Abstract

Aims: This study was to evaluate the efficacy and safety of maintenance therapy with capecitabine following induction chemotherapy in patients with metastatic colorectal cancer. Patient and Method: Between October 2019 and Ferbruary 2022, 68 patients were enrolled in the study in Vietnam National cancer Hospital. Patients who completed induction chemotherapy and achieved disease control were received maintenance therapy of capecitabine until disease progression or unacceptable toxicity. Results: Mean age was 58,4 years; 42,6% had rectal primary tumor, 32,4% had left-sight colon primary tumor, 25% had right-sight colon primary tumor; metachronous occurred in 73,5% patients. Histopathological result were 88,2% adenocarcinoma, 11,8% mucinous adenocarcinoma. The most common site of metastasis was the liver (67.6%), followed by the lung (26.5%) and the peritoneum (19.1%). The first-line regimen with oxaliplatin-base was 75%, irinotecan-base was 25%. After induction treatment partial response was 73,5% and 19,1% had stable disease. The median progression-free survival (PFS) after maintenance therapy was 8.7 months. Progression-free survival after induction chemotherapy (PFS1) was 15.2 months. The most common side effects are grade 1,2 with hand and foot syndrome 21.2%; anemia 3.1%; neutropenia 4.8%; thrombocytopenia 5.7%. Conclusion: Maintenance treatment with capecitabinn in patients with metastatic colorectal cancer is effective and does not compromise quality of life.